Compare Stocks

→ Do This Today BEFORE Biden Wins in November (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMK MacDonald Mines Exploration	C$0.04 +14.3%	C$0.05	C$0.03 ▼ C$0.09	C$1.52M	0.4	71,898 shs	28,700 shs
KLDO Kaleido Biosciences		$0.00	$0.00 ▼ $0.25	$6.39M	-0.06	3,654 shs	2,240 shs
LXRX Lexicon Pharmaceuticals	$1.79 -5.3%	$2.03	$0.92 ▼ $3.73	$440.76M	1.38	4.22 million shs	2.05 million shs
PLSE Pulse Biosciences	$7.45 +7.2%	$8.30	$3.78 ▼ $13.62	$426.89M	1.73	155,686 shs	150,200 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMK MacDonald Mines Exploration	0.00%	+14.29%	-20.00%	0.00%	-33.33%
KLDO Kaleido Biosciences	0.00%	0.00%	0.00%	0.00%	-50.00%
LXRX Lexicon Pharmaceuticals	+6.78%	+11.18%	-8.70%	-20.92%	-38.44%
PLSE Pulse Biosciences	+0.72%	-13.66%	-7.70%	-17.06%	-16.27%

Biggest hedge fund manager has huge warning for U.S. dollar (Ad)

Prescient CEO Makes Shocking New Prediction Known for his eerily accurate market calls over the years, this CEO has just revealed his newest prediction about "America's New Money."

Get the details before it's taken offline.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BMK MacDonald Mines Exploration	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KLDO Kaleido Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	1.8053 of 5 stars	3.3	1.0	0.0	0.0	3.1	1.7	0.6
PLSE Pulse Biosciences	0.748 of 5 stars	0.0	1.0	0.0	4.2	2.0	3.3	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMK MacDonald Mines Exploration	N/A	N/A	N/A	N/A
KLDO Kaleido Biosciences	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	2.67	Moderate Buy	$5.00	179.33% Upside
PLSE Pulse Biosciences	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest KLDO, PLSE, BMK, and LXRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/3/2024	LXRX Lexicon Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold
4/30/2024	LXRX Lexicon Pharmaceuticals	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
4/30/2024	LXRX Lexicon Pharmaceuticals	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
4/23/2024	LXRX Lexicon Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold
4/11/2024	LXRX Lexicon Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold

(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMK MacDonald Mines Exploration	C$-74K	-20.48	C$0.00 per share	13.00	C($0.01) per share	-4.00
KLDO Kaleido Biosciences	$1.10M	0.00	N/A	N/A	N/A	NaN
LXRX Lexicon Pharmaceuticals	$2.31M	190.81	N/A	N/A	$0.38 per share	4.71
PLSE Pulse Biosciences	$700K	587.70	N/A	N/A	$0.81 per share	9.20

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMK MacDonald Mines Exploration	-C$1.28M	-C$0.02	N/A	∞	N/A	N/A	-1,679.48%	-174.36%	6/4/2024 (Estimated)
KLDO Kaleido Biosciences	N/A	-$2.24	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	-$177.12M	-$0.83	N/A	N/A	N/A	-8,311.12%	-108.54%	-61.97%	8/1/2024 (Estimated)
PLSE Pulse Biosciences	-$42.21M	-$0.89	N/A	∞	N/A	N/A	-112.74%	-61.09%	8/8/2024 (Estimated)

Latest KLDO, PLSE, BMK, and LXRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/28/2024	Q4 2023	PLSE Pulse Biosciences	N/A	-$0.21	-$0.21	-$0.20	N/A	N/A
3/11/2024	Q4 2023	LXRX Lexicon Pharmaceuticals	-$0.23	-$0.20	+$0.03	-$0.20	$0.68 million	$0.70 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMK MacDonald Mines Exploration	N/A	N/A	N/A	N/A	N/A
KLDO Kaleido Biosciences	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PLSE Pulse Biosciences	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMK MacDonald Mines Exploration	3.84	0.18	0.27
KLDO Kaleido Biosciences	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	0.35	15.58	15.56
PLSE Pulse Biosciences	N/A	6.76	6.76

Ownership

Institutional Ownership

Company	Institutional Ownership
BMK MacDonald Mines Exploration	0.79%
KLDO Kaleido Biosciences	81.56%
LXRX Lexicon Pharmaceuticals	74.70%
PLSE Pulse Biosciences	76.95%

Insider Ownership

Company	Insider Ownership
BMK MacDonald Mines Exploration	5.45%
KLDO Kaleido Biosciences	9.00%
LXRX Lexicon Pharmaceuticals	6.80%
PLSE Pulse Biosciences	71.50%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
BMK MacDonald Mines Exploration	2	37.88 million	N/A	Not Optionable
KLDO Kaleido Biosciences	76	42.62 million	38.79 million	Not Optionable
LXRX Lexicon Pharmaceuticals	285	246.24 million	235.16 million	Optionable
PLSE Pulse Biosciences	61	55.22 million	15.74 million	Optionable

KLDO, PLSE, BMK, and LXRX Headlines

Source	Headline
	Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System finance.yahoo.com - May 9 at 8:09 AM
	Pulse Biosciences Inc (PLSE) Q1 2024 Earnings Call Transcript Highlights: Strategic ... finance.yahoo.com - May 8 at 4:47 AM
	PLSE Stock Earnings: Pulse Biosciences Reported Results for Q1 2024 investorplace.com - May 7 at 11:03 PM
	Pulse Biosciences Reports Q1 2024 Financial Results Amidst Strategic Business Developments finance.yahoo.com - May 7 at 6:47 PM
	Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results businesswire.com - May 7 at 4:05 PM
	Pulse Biosciences (PLSE) to Release Quarterly Earnings on Tuesday americanbankingnews.com - May 5 at 5:36 AM
	Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000 businesswire.com - May 2 at 8:00 AM
	5 ChatGPT Penny Stock Picks Right Now insidermonkey.com - April 28 at 2:41 PM
	Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024 businesswire.com - April 24 at 4:05 PM
	Pulse Biosciences to raise $60M massdevice.com - March 29 at 10:48 AM
	Q4 2023 Pulse Biosciences Inc Earnings Call finance.yahoo.com - March 29 at 10:48 AM
	PLSE Stock Earnings: Pulse Biosciences Reported Results for Q4 2023 investorplace.com - March 28 at 11:31 PM
	Pulse Biosciences Inc (PLSE) Reports Increased GAAP Costs and Narrowed Net Loss in 2023 finance.yahoo.com - March 28 at 7:45 PM
	Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results businesswire.com - March 28 at 4:12 PM
	Pulse Biosciences Announces Plans to Initiate a Rights Offering businesswire.com - March 28 at 4:10 PM
	PLSE Apr 2024 25.000 call finance.yahoo.com - March 17 at 10:01 AM
	PLSE Oct 2024 17.500 call finance.yahoo.com - March 17 at 12:13 AM
	PLSE Oct 2024 12.500 call finance.yahoo.com - March 16 at 2:13 PM
	PLSE Jul 2024 2.500 put finance.yahoo.com - March 16 at 2:13 PM
	Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024 businesswire.com - March 14 at 4:05 PM
	Pulse Biosciences’s CellFXnsPFA system secures FDA 510(k) clearance msn.com - March 13 at 7:07 PM
	FDA clears pulsed field ablation electrode tech from Pulse Biosciences massdevice.com - March 11 at 1:28 PM
	What to know about low blood pressure with a high pulse medicalnewstoday.com - March 10 at 2:46 PM
	FDA clears Pulse Biosciences' soft tissue ablation system investing.com - March 10 at 2:46 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

MacDonald Mines Exploration

CVE:BMK

MacDonald Mines Exploration Ltd. engages in the acquisition, exploration, and development of mineral properties in Canada. The company explores for gold, silver, copper, cobalt, and nickel deposits. It owns 100% interest in the Scadding-Powerline-Jovan property that covers an area of 19,710 hectares located to the east of Sudbury in Northern Ontario. The company was formerly known as MacDonald Mines Limited. MacDonald Mines Exploration Ltd. was incorporated in 1936 and is based in Toronto, Canada.

Kaleido Biosciences

NASDAQ:KLDO

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Lexicon Pharmaceuticals

NASDAQ:LXRX

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Pulse Biosciences

NASDAQ:PLSE

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial